Identification and Functional Characterization of PI3K/Akt/mTOR Pathway-Related lncRNAs in Lung Adenocarcinoma: A Retrospective Study

Identification and Functional Characterization of PI3K/Akt/mTOR Pathway-Related lncRNAs in Lung Adenocarcinoma: A Retrospective Study

Blog Article

Objective: This paper aimed to investigate the PI3K/Akt/mTOR signal-pathway regulator factor-related lncRNAsignatures (PAM-SRFLncSigs), associated with regulators of the indicated signaling pathway in patients with lungadenocarcinoma (LUAD) undergoing immunotherapy.Materials and Methods: In this dodge warlord for sale retrospective study, we employed univariate Cox, multivariate Cox, and least absoluteshrinkage and selection operator (LASSO) regression analyses to identify prognostically relevant long non-codingRNAs (lncRNAs), construct prognostic models, and perform Gene Ontology (GO) and Kyoto Encyclopedia of Genesand Genomes (KEGG) analyses.Subsequently, immunoassay and chemotherapy drug screening were conducted.Finally, the prognostic model was validated using the Imvigor210 cohort, and u11-200ps tumor stem cells were analyzed.Results: We identified seven prognosis-related lncRNAs (AC084757.

3, AC010999.2, LINC02802, AC026979.2,AC024896.1, LINC00941 and LINC01312).We also developed prognostic models to predict survival in patientswith LUAD.

KEGG enrichment analysis confirmed association of LUAD with the PI3K/Akt/mTOR signaling pathway.In the analysis of immune function pathways, we discovered three good prognostic pathways (Cytolytic_activity,Inflammation-promoting, T_cell_co-inhibition) in LUAD.Additionally, we screened 73 oncology chemotherapy drugsusing the "pRRophetic" algorithm.Conclusion: Identification of seven lncRNAs linked to regulators of the PI3K/Akt/mTOR signaling pathway providedvaluable insights into predicting the prognosis of LUAD, understanding the immune microenvironment and optimizingimmunotherapy strategies.